OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Cardiology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Anticipating Pharmacological Perturbation With Human Genetic Variation—Lessons From CETP	291
A Woman With Recurrent Torsade de Pointes	237
A Patient in His 50s With Chest Tightness and Left Arm and Neck Tingling	234
The Case for Inclusion of a Lipid Panel in the Standard Precatheterization Laboratory Blood Draw—Stating What Should Be Obvious	226
Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction—Reply	204
Error in Table 1	184
Educational Attainment and Cardiovascular Risk—A Missed Opportunity?	161
JAMA Cardiology	154
Mendelian Randomization and Cardiovascular Disease—Enabling Expert Readership	153
Ventricular Septal Rupture After ST-Segment Elevation Myocardial Infarction	141
Implementing Shared Decision-making for Patients With Aortic Stenosis With Longer Life Expectancy	130
JAMA Cardiology	124
Mining the Electronic Medical Record for Hypertension Treatment—Hope or Hype?	121
Accountable Care Organization Participation and Cardiovascular Care Quality	118
Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure	118
Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event—Moving Beyond C Statistic	113
Primary Prevention Management of Elevated Lipoprotein(a)	113
Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction	112
Genome-Wide Association Study of Accessory Atrioventricular Pathways	109
Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF	106
Myocardial Fibroblast Activation in Ischemic and Nonischemic Cardiomyopathy	105
Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors	101
USPSTF Report on Aspirin for Primary Prevention	101
Error in Author Surname	100
Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease	100

Chest Pain in a Middle-Aged Man	98
JAMA Cardiology Peer Reviewers in 2025	95
Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement	95
Competitive Native Flow and Coronary Bypass Graft Patency in AAOCA	94
Blood Pressure Measurements From Self-Service Health Kiosks in US Retail Stores, 2017-2024	92
Multiple Endotypes and Angina Burden in Patients With Nonobstructive Coronary Arteries	91
Long-Term Changes in Ventricular Function in Recreational Marathon Runners	88
Spontaneous Coronary Artery Dissection in a Healthy Man With Non–ST Elevation Myocardial Infarction	86
High-Intensity Interval Training vs Moderate-Intensity Continuous Training for Women Undergoing Cardiovascular Rehabilitation	85
JAMA Cardiology	85
Supraventricular Tachycardia Following Mitral Valve Surgery	84
JAMA Cardiology	83
Influenza Vaccine in High-Risk Cardiovascular Diseases—Define the Target—Reply	79
What Is Your Secret to Health?	79
Peak Oxygen Uptake vs Ventilatory Efficiency	78
Interpreting Health Status Measures in Patients With Heart Failure—What Counts	78
Race, Racism, and Risk—Implications of Social Determinants of Health in Cardiovascular Disease Prediction	77
Beware the Possible Dangers of Chemsex—Is Illicit Drug–Related Sudden Cardiac Death Underestimated?	75
User Trust in Artificial Intelligence–Guided Lung Ultrasound	74
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone	74
Innovation in Event Adjudication—Human vs Machine	72
Burden of Rare Genetic Variants in Spontaneous Coronary Artery Dissection With High-risk Features	71
Critical Appraisal of the Negative Predictive Performance of the European Society of Cardiology 0/1-Hour Algorithm for Evaluating Patients With Chest Pain in the US	67
Contribution of Clinical Trial Event Data by Data Source	67
Left Atrial Appendage Closure After Thrombus Aspiration—Reply	67
Evidence-Based Imaging Pathway for Atrial Fibrillation Ablation	65
Corrected to Open Access Status	63
Artificial Intelligence–Guided Lung Ultrasound by Nonexperts	63
Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction	63
Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease	63
Circulating Trimethylamine N-Oxide and Growth Rate of Abdominal Aortic Aneurysms and Surgical Risk	63
Achieving Equitable Access to Acute Myocardial Infarction Therapies for Rural Patients—Is It Possible?	62
Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency	62
Young Man With Coarctation of the Aorta	61
PCSK9 in Familial Hypercholesterolemia and Beyond	61
JAMA Cardiology	61
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	60
Geographical and Urban-Rural Disparities in Cardiac Rehabilitation Eligibility and Center-Based Use in the US	60
JAMA Cardiology	59
Epicardial and Pericardial Fat—Separated But Under the Same Roof—Reply	58
Error in Figure	57
Supine Blood Pressure and Risk of Cardiovascular Disease and Mortality	57
Circumferential Pulmonary Vein Isolation With vs Without Additional Low-Voltage-Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation	57
Clinical Decisions and Outcomes After Switching High-Sensitivity Cardiac Troponin Assays in Suspected ACS	57
Professional Preferences and Perceptions of Cardiology Among Internal Medicine Residents	57
Optimizing Cascade Testing to Advance Health Equity in Cardiac Amyloidosis	57
Error in Nonauthor Collaborator’s Name	56
Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events	55
Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes	55
Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia	55

Potassium Nitrate in Heart Failure With Preserved Ejection Fraction	54
Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes	54
Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1	53
Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk	53
High-Intensity Interval Training vs Moderate-Intensity Continuous Training for Women Undergoing Cardiovascular Rehabilitation	52
A Woman With Syncope and Frequent Premature Ventricular Contractions	51
Passing the Stethoscope	51
Exertional Dyspnea in a Female Patient Aged 55 Years Without Significant Medical History	51
The Politics of HFpEF—What’s Good for the Left Is Good for the Right	50
Importance of Prolonged QRS Duration in Detecting Complete Conduction Block	50
The Urgent Need to Improve Outcomes for Pregnant Cardiovascular Trainees	50
Error in Abstract and Results	50
Error in Figure 1	49
Troponins and Pregnancy—Reply	49
Athletes With Cardiovascular Disease and Competitive Sports Eligibility	49
The 3.5-Inch View—On Perspective and the Medical Profession	48
A New His-Ventricular Threshold for Myotonic Dystrophy Type 1—Reply	48
Current Landscape and Future Directions of Coronary Revascularization in Patients With Heart Failure	48
Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US	47
When Is a Placebo Not a Placebo	46
Prioritizing the Exposome to Reduce Cardiovascular Disease Burden	46
Clonal Hematopoiesis—Fuel to Inflame the Heart	45
Cardiac Fibrosis—An Emerging Diagnostic and Therapeutic Target	44
Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease	44
US Trends in Prescribing Nonstatin Lipid-Lowering Therapy, 2019-2024	44
Preserving and Promoting Clinical Trial Representativeness	43
High-Sensitivity Troponin T and I Among Pregnant Women in the US—The National Health and Nutrition Examination Survey, 1999-2004	43
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy	43
State-Level Cardiovascular Mortality Rates Among Hispanic, Non-Hispanic Black, and Non-Hispanic White Populations, 1990 to 2019	43
Concomitant Mechanical Aspiration and Appendage Closure for Recalcitrant Left Atrial Appendage Thrombi	43
Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes	43
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines	42
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials	42
Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure—A Call to Action	42
Early Mortality in Type A Acute Aortic Dissection	42
Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity	42
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US	42
Assessment for Long-Term Cardiovascular Disease Risk in Pregnancy	41
JAMA Cardiology	41
The Smart(est) Choice for Dual Antiplatelet Therapy Is a Patient-Directed One	40
Incidental Complication From a Left Atrial Appendage Device	40
Is CABG Indicated in Patients With Ischemic Cardiomyopathy?	40
An Elderly Woman With Ventricular Tachycardia	39
JAMA Cardiology	39
A 65-Year-Old Woman With Dyspnea and Recurrent Abdominal Distension	39
Corrected to Open Access Status	39
My Grandfather’s Blueprint	39
Errors in Author Affiliations and Open Access Updated	39
Error in Abstract	38
Indication Creep in Transcatheter Aortic Valve Implantation—Data or Desire?	37
Error in Table	37
Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure	37
Reflections of an Editorial Fellow—A Window Into Medical Publishing	37
In Honor of the Pig	36
Preventing Declines in Cardiovascular Health From Childhood	36
Error in Abstract and Text	35
The Limitations and Risks Associated With Semaglutide Treatment—Reply	35
Error in Results	34
One-Year Outcomes of Coronary Angiography After Out-of-Hospital Cardiac Arrest Without ST Elevation	34
Predicting the Risk of Myocardial Infarction vs the Risk of Stroke in Hypertension—Reply	34
Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis	34
Improving Behavioral Counseling for Primary Cardiovascular Disease Prevention	33
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure	33
Finerenone in Heart Failure—Reply	33
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation	33
The Last Mile in Prevention—Can Coronary CT Angiography Help?	33
Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations	32
Cardiovascular Health Among Rural and Urban US Adults—Healthcare, Lifestyle, and Social Factors	32
Interpreting AI-Enhanced ECG Performance in High-Risk, Resource-Limited Settings	32
Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality	32
PREVENT Risk Age Equations and Population Distribution in US Adults	32
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV	32
Effectiveness of a Text-Based Gamification Intervention to Improve Physical Activity Among Postpartum Individuals With Hypertensive Disorders of Pregnancy	31
A Young Woman With Dyspnea During Cardiac Catheterization	31
Medicine, Writing, and the Limits of Language	31
Moving Beyond Conventional Guesstimation to Guide PCI	30
Comment on Aspirin Avoidance in Patients With LVADs	30
JAMA Cardiology	30
Fontan Junctional Rhythm—Innocent Bystander or Silent Killer?	30
Medical Editors vs Nuclear Weapons—Is the Pen Mightier Than the Sword?	30

Alternative Certification Methods for Cardiac Proceduralists	30
What Role for New York Heart Association Class in Heart Failure Clinical Trials?	30
Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk	29
Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement	29
Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	29
Trends in Transcatheter vs Surgical Mitral Valve Repair Among Medicare Beneficiaries, 2012 to 2019	29
High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients With Acute Pulmonary Embolism	29
Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures	28
Structural Assumptions in Semaglutide Cost-Effectiveness	28
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial	28
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock	28
Machine Learning–Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure	28
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	28
Man in His Sixth Decade of Life With Totally Occluded Abdominal Aorta (Leriche Syndrome)	27
A Man in His 20s With Gradually Enlarging Mediastinal Mass and Intermittent Hemoptysis	27
More Attention Should Be Paid to Less Severe Nonculprit Lesions—Reply	27
How Do We Credit the Evidence Generated From Subgroup Analyses in Randomized Clinical Trials?—Reply	27
JAMA Cardiology	27
Polygenic Susceptibility in Peripartum, Alcohol-Induced, and Cancer Therapy–Related Cardiomyopathies	26
The Fine Art and Science of Translating Trials Results Into Clinical Practice	26
Is There a Need for Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction?	26
Myocardial Dysfunction in Primary Mitral Regurgitation	26
JAMA Cardiology	26
Distinct Genetic Risk Profile in Aortic Stenosis Compared With Coronary Artery Disease	25
Exertional Syncope in a Female Teenage Student	25
Plasma Proteomics of Exercise Blood Pressure and Incident Hypertension	25
Trends in 10-Year Outcomes Among Medicare Beneficiaries Who Survived an Acute Myocardial Infarction	25
Everything Right, Everything Wrong	25
Nudging to Improve Cardiovascular Care—Clinicians, Patients, or Both	25
Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension	25
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management	24
Quality of Care and Clinical Outcomes for Patients With Heart Failure at Hospitals Caring for a High Proportion of Black Adults	24
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	24
Emergency Medical Service Agency Practices and Cardiac Arrest Survival	24
Patient Enrollment for Cardiovascular Clinical Trials in the United States	24
Coronary Angiography After Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation	24
Beware the Possible Dangers of Chemsex—Is Illicit Drug–Related Sudden Cardiac Death Underestimated?—Reply	23
Influenza Vaccine in High-Risk Cardiovascular Diseases—Define the Target	23
Transient Monocular Blindness in a Man in His 30s	23
Error in Abstract and Methods	23
Genetic Testing in Early-Onset Atrial Fibrillation	23
Chest Tube–Induced Right Ventricular Failure After Cardiac Surgery	23
Salt Substitution and Recurrent Stroke and Death—Reply	22
Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US	22
Blood Pressure Control After SPRINT—Back to Reality	22
Inquiry Regarding Body Temperature Data in HuMAIN-HFpEF Trial	22
JAMA Cardiology	22
Performance of the European Society of Cardiology 0/1-Hour Algorithm With High-Sensitivity Cardiac Troponin T Among Patients With Known Coronary Artery Disease	22
Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation	22
Women’s Representation in Interventional Cardiology	22
Hospitalization Rates Alone Do Not Define Health Systems—Reply	22
Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery	22
Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction	22
Hard Lessons From a School-Based Intervention to Improve Cardiovascular Health in Adolescence	22
Heart Failure and Nonoptimal Temperatures	22
Private Equity and Cardiovascular Health Care	21
The Cost-Effectiveness Evolution of Cardiovascular Care	21
Time to Revisit Using 10-Year Risk to Guide Statin Therapy	21
High-Risk Areas—The Trees in the Forest—Reply	21
Carotid Artery Stenosis—An Impactful Bias in Ischemic Stroke Classification	21
Emergency Department–Based Education and mHealth Empowerment Intervention for Hypertension	21
Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation	20
AI-Assisted Point-of-Care Ultrasound Networks—Considerations for Rural Health Care Delivery	20
Pathological Analysis of Lipoprotein(a) Risk Variants and Culprit Coronary Thrombotic Lesions	20
Long-term Survival After Out-of-Hospital Cardiac Arrest	20
From the Heart: Eugene Braunwald (1929-2026)	20
Educational Attainment and Lifetime Risk of Cardiovascular Disease	20
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients	20
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy	20
Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer	19
Recommendations for Deferred Testing in Low-Risk Chest Pain—Decades Old But Now Finally Tested	19
Variants at the Interleukin 1 Gene Locus and Pericarditis	19
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020	19
Heart Failure—Together We Go Farther—Reply	19
Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan	19
Reducing the Risks of Nuclear War—The Role of Health Professionals	19
Error in Figure 1	18
Errors in Abstract	18
What’s VAT All About—The Clue Is in the Genetics	18
Implantable Cardioverter-Defibrillators in Chagas Cardiomyopathy—Reply	18
Can Noncalcified Plaques Contribute to Future Coronary Events?	18
Pathway to Risk Stratification in Tricuspid Regurgitation	18
Exercise-Induced Dyspnea in an Older Woman With a History of Coronary Artery Disease	18
Management of Postpartum Left Main Spontaneous Coronary Artery Dissection	18
Evidence Generation for Novel Cardiovascular Devices—Putting the Horse Back in Front of the Cart	18
Error in Figure	17
Early Rule Out With a Refreshed Troponin Assay	17
Electrocardiographic Findings in Female Professional Basketball Athletes	17
Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease	17
Social Vulnerability and Poor Health Outcomes	17
Prioritizing Time from Diagnosis to Quadruple Therapy in Heart Failure Care	17
Sex Differences in Left Ventricular Remodeling and Outcomes in Aortic Regurgitation	17
Echoes of Concern—AI and Moral Agency in Medicine	16
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults	16
Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy	16